Integrated nanomaterials offer new strategies for cancer immunotherapy

Immune checkpoint inhibitors, cancer vaccines and cellular therapies have reshaped oncology, yet most patients still do not achieve lasting benefit. Solid tumors form layered defenses: abnormal blood vessels and dense tissue restrict drug access, unstable antigen expression weakens immune recognition, and suppressive cells, cytokines and metabolic conditions exhaust tumor-fighting lymphocytes. Systemic stimulation can also cause immune-related adverse events, creating a difficult balance between potency and safety. Nanomaterials offer adjustable size, surface chemistry and cargo capacity, but systems designed around only one barrier may fail elsewhere in the treatment pathway. Based on these challenges, in-depth research is needed into integrated nanomaterials that coordinate tumor delivery, antigen presentation and immune microenvironment reprogramming.

Researchers from Nankai University published (DOI: 10.1007/s10118-026-3567-z) the review online on April 24, 2026, in Chinese Journal of Polymer Science. The study summarizes three complementary nanomaterial strategies designed to overcome physiological barriers, enhance tumor immunogenicity and relieve immune suppression, providing a unified framework for developing more precise and effective bioactive nanomaterials for cancer immunotherapy and clarifying how these approaches may be integrated.

The first route centers on surface-adaptive nanomaterials (SANs), which remain relatively stable during circulation but respond to acidity or hypoxia inside tumors. These changes can expose adhesive surfaces, improve tumor retention or trigger controlled release of immune-regulating cargo. The second route uses antigen engineering to restore immune visibility. Some nanoplatforms anchor immunogenic signals onto tumor-cell membranes, helping natural killer (NK) cells or tumor-associated macrophages recognize malignant cells. Others induce endoplasmic reticulum stress or lysosomal disruption, prompting cancer cells to display immunogenic signals and release damage-associated molecular patterns (DAMPs). Additional systems capture tumor-associated antigens (TAAs) and deliver them to antigen-presenting cells (APCs), particularly dendritic cells (DCs), to support major histocompatibility complex class I (MHC-I) presentation and T-cell activation. The third route reshapes the tumor microenvironment (TME) by concentrating checkpoint inhibitors within tumors, removing suppressive proteins or regulating immune-related pathways at the gene level. Studies summarized in the review reported stronger tumor control, reduced metastasis or improved immune activation in mouse models. Across these examples, the authors argue that circulation stability, tumor-selective activation, antigen presentation and immune reprogramming should be designed as connected functions rather than separate technical goals.

The authors said bioactive nanomaterials should be viewed not simply as passive carriers, but as responsive systems that interact with changing biological conditions. A clinically useful platform must remain controlled in the bloodstream, activate selectively within tumors, strengthen immune recognition and reduce local suppression, they said. The authors added that progress will depend on clearer understanding of nano-bio interactions, stronger immune-safety testing, predictable biodistribution, durable immune memory and manufacturing methods that can deliver reproducible materials at clinical scale, rather than only dramatic tumor shrinkage in small animal studies

The framework could support nanomedicines tailored to a patient's tumor antigens, immune status and microenvironment. Future platforms may combine programmable materials with engineered cells, ribonucleic acid (RNA) circuits, gene-editing tools, radiotherapy, chemotherapy or targeted inhibitors to widen therapeutic windows and overcome resistance. Translation will require standardized assessment of cytokine release, complement activation, off-target immune stimulation, pharmacokinetics, clearance and long-term protection against tumor recurrence. Good manufacturing practice (GMP)-compatible production and quality control (QC) will also be essential for batch consistency, stability, sterility and scalability. Building these requirements into early design could help move promising preclinical systems toward clinical testing for immunotherapy-resistant cancers.